| 0.2238 -0.004 (-1.84%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.37 | 1-year : | 0.45 |
| Resists | First : | 0.31 | Second : | 0.38 |
| Pivot price | 0.29 |
|||
| Supports | First : | 0.2 | Second : | 0.17 |
| MAs | MA(5) : | 0.22 |
MA(20) : | 0.31 |
| MA(100) : | 0.35  |
MA(250) : | 0.33 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.7 |
D(3) : | 8.1 |
| RSI | RSI(14): 27.1 |
|||
| 52-week | High : | 0.85 | Low : | 0.18 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PHGE ] has closed above bottom band by 14.4%. Bollinger Bands are 23.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.24 - 0.24 | 0.24 - 0.24 |
| Low: | 0.22 - 0.22 | 0.22 - 0.22 |
| Close: | 0.22 - 0.22 | 0.22 - 0.23 |
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Wed, 10 Jul 2024
BiomX Inc. Announces Stockholder Approval for Conversion of - GlobeNewswire
Thu, 30 May 2024
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards - Yahoo Finance
Wed, 22 May 2024
BiomX Inc. (AMEX:PHGE) Q1 2024 Earnings Call Transcript - Insider Monkey
Mon, 11 Mar 2024
BiomX, APT merger to advance CF treatment BX004 into Phase 2 trial - Cystic Fibrosis News Today
Wed, 06 Mar 2024
Phage therapy co BiomX merges with APT, raises $50m - Globes
Wed, 06 Mar 2024
BiomX Merger and Strategic Equity Deals Reshape Future - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 26.4 (%) |
| Held by Institutions | 16.2 (%) |
| Shares Short | 98 (K) |
| Shares Short P.Month | 8 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.8 % |
| Return on Equity (ttm) | -153.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.36 |
| PEG Ratio | 0 |
| Price to Book value | 1.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|